Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205.

Abstract

There is a Blood Commentary on this article in this issue.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution / genetics
  • Antineoplastic Agents / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
  • Cohort Studies
  • DNA Mutational Analysis
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics
  • Gene Frequency
  • Glycine / genetics
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Models, Molecular
  • Mutation
  • Mutation Rate*
  • Proto-Oncogene Proteins c-bcl-2 / chemistry
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Sulfonamides / therapeutic use*
  • Tumor Cells, Cultured
  • Valine / genetics

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Valine
  • venetoclax
  • Glycine